Shares of 10x Genomics Inc reached a 52-week high of $37.58, marking a significant milestone for the company. At the time of the report, the stock was trading at $37.30, with a total market capitalization of $4.72 billion. This price movement reflects a substantial recovery over the past year, with the stock surging by 221% over a one-year period.
The recent price action follows several corporate developments. 10x Genomics announced the acquisition of Proteintech Genomics, a division of Proteintech Group. This transaction is intended to enhance the company’s capabilities in multimodal analysis and proteomics. The integration includes technologies such as the Human Discovery Panel. Additionally, the company entered a multi-year research collaboration with the Cleveland Clinic. This partnership focuses on discovering biomarkers for bladder cancer and will utilize platforms including Flex Apex and Xenium, with potential expansion to the Atera platform.
Market reactions to these developments have been varied. Canaccord reiterated a Buy rating for 10x Genomics, maintaining a price target of $32.00 following the acquisition announcement. However, data from InvestingPro suggests the stock may be overvalued relative to its fair value analysis. The platform also indicated overbought signals, noting that the stock is trading near its 52-week high.
Other market movements were noted but did not directly impact 10x Genomics. TD Cowen reported shifts in short interest among life science tools stocks, though 10x Genomics was not highlighted as having significant changes in this area. After-hours trading showed the stock closing at $39.01, with a slight decline of $0.04, or 0.10%, from the previous close. The after-hours price reached $39.16, up $0.15 or 0.38%.
The company’s performance highlights investor confidence in its future prospects. The acquisition and research partnerships are part of ongoing efforts to advance research and technological capabilities. While the stock has experienced strong growth, some analysts caution about potential overvaluation. Further details regarding the long-term impact of these developments are not yet clear.
